NCT05266872 Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme
| NCT ID | NCT05266872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Luxembourg Institute of Health |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2014-12-19 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,800 participants in total. It began in 2014-12-19 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
Eligibility Criteria
Inclusion Criteria: * Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism) * Subjects of all genders with a full capacity of consent * Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement * Subjects of at least 18 years of age at the time of inclusion Exclusion Criteria: * Refusal to sign the informed consent * Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion * Active cancer * Pregnant women * Underage subjects of less than 18 years of age * Refusal to comply with mandatory sample collection * For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.
Contact & Investigator
Rejko Rejko, Dr
PRINCIPAL INVESTIGATOR
Luxembourg Institute of Health
Frequently Asked Questions
Who can join the NCT05266872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05266872 currently recruiting?
Yes, NCT05266872 is actively recruiting participants. Contact the research team at rejko.krueger@uni.lu for enrollment information.
Where is the NCT05266872 trial being conducted?
This trial is being conducted at Luxembourg, Luxembourg, Luxembourg, Luxembourg.
Who is sponsoring the NCT05266872 clinical trial?
NCT05266872 is sponsored by Luxembourg Institute of Health. The principal investigator is Rejko Rejko, Dr at Luxembourg Institute of Health. The trial plans to enroll 1,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.